Skip to main content
Terug
Watch Compare

LISATA THERAPEUTICS, INC.

Datakwaliteit: 100%
LSTA
Nasdaq Manufacturing Chemicals
€ 5,01
▲ € 0,01 (0,10%)
Marktkapitalisatie: 45,21 M
Prijs
€ 5,01
Marktkapitalisatie
45,21 M
Dagbereik
€ 5,00 — € 5,01
52-Weeksbereik
€ 1,81 — € 5,07
Volume
10.505
Openen € 5,00
50D / 200D Gem.
€ 4,68
6,96% above
50D / 200D Gem.
€ 2,95
69,51% above

Quick Summary

Belangrijkste Punten

Negative free cash flow of -17,26 M
Capital efficient — spends only 2,62% of revenue on capex

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-95,01%
Onder sectorgemiddelde (-53,41%)
ROIC-83,40%
Net Margin-1704,86%
Op. Margin-1876,54%

Veiligheid

Debt / Equity
N/A
Current Ratio4,72
Interest CoverageN/A

Waardering

PE (TTM)
-2,48
Onder sectorgemiddelde (-1,48)
P/B Ratio2,60
EV/EBITDAN/A
Dividend YieldN/A

Koershistorie

Financiële Trends

Sectorvergelijking

vs Manufacturing sector mediaan (1364 peers)
Metriek Aandeel Sector Mediaan
P/E -2,5 -1,5
P/B 2,6 1,6
ROE % -95,0 -53,4
Net Margin % -1704,9 -41,5
Rev Growth 5Y % — 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) N/A Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 1,07 M Net Income (TTM) -18,24 M
ROE -95,01% ROA -77,76%
Gross Margin N/A Operating Margin -1876,54%
Net Margin -1704,86% Free Cash Flow (TTM) -17,26 M
ROIC -83,40% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 4,72
Interest Coverage N/A Asset Turnover 0,05
Working Capital 17,01 M Tangible Book Value 16,97 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -2,48 Forward P/E N/A
P/B Ratio 2,60 P/S Ratio 42,25
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -38,17%
Market Cap 45,21 M Enterprise Value 26,21 M
Per Share
EPS (Diluted TTM) -2,13 Revenue / Share 0,12
FCF / Share -1,91 OCF / Share -1,91
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 2,62% FCF Conversion 94,59%
SBC-Adj. FCF N/A Growth Momentum N/A

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Revenue 1,00 M 0,0 — — —
Net Income -19,99 M -20,84 M -54,23 M -27,47 M -8,15 M
EPS (Diluted) -2,40 -2,58 -10,47 -0,50 —
Gross Profit — — — — —
Operating Income -22,41 M -25,71 M -57,60 M -29,05 M -19,15 M
EBITDA — — — — —
R&D Expenses — — — 17,68 M 9,25 M
SG&A Expenses — 12,97 M 14,14 M 11,37 M 9,89 M
D&A 174.000,0 189.000,0 69.000,0 55.000,0 100.000,0
Interest Expense — — — — —
Income Tax -798.000,0 -2,33 M -2,48 M -1,51 M -10,87 M

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 35,00 M 54,69 M 73,03 M 97,01 M 36,00 M
Total Liabilities 5,69 M 6,80 M 6,71 M 5,01 M 3,76 M
Shareholders' Equity 29,57 M 48,15 M 66,58 M 92,25 M 32,50 M
Total Debt — — — — —
Cash & Equivalents 16,21 M 22,59 M 32,15 M 24,65 M 16,51 M
Current Assets 34,58 M 53,92 M 71,88 M 96,18 M 35,33 M
Current Liabilities 5,61 M 6,59 M 6,38 M 4,52 M 3,51 M